Since none of the new drugs has the potential to eradicate the disease, patients will in future be referred for alloHCT with a treatment history including use of these drugs.

**Studies on the impact of Ibrutinib and Idelalisib administered prior to and after alloHCT**

The CLL subgroup committee focuses with its current studies on the administration of Ibrutinib and Idelalisib in the context of alloHCT.

The major goal of these studies is to evaluate safety issues of such treatment sequences and to assess their efficacy in terms of long-term disease control.

**Ibrutinib prior to alloHCT:** P. Dreger et al.

**Idelalisib prior to alloHCT:** J. Schetelig et al.

**Ibrutinib after alloHCT:** M. Michallet et al.

**Idelalisib after alloHCT:** P. Dreger et al.

Results of a preliminary analysis on 14 patients do not raise concerns about the safety of Ibrutinib in the post alloHCT setting, especially not about the risk of excessive induction of GVHD.